Sökning: "rituximab"
Visar resultat 1 - 5 av 61 avhandlingar innehållade ordet rituximab.
1. Treatment with the monoclonal antibody rituximab in Multiple Sclerosis : a study based on an academic clinical trial
Sammanfattning : Background: Multiple sclerosis (MS) is a chronic, inflammatory disease, affecting the central nervous system. A growing number of disease modifying treatment alternatives entails a need for an individualised risk-benefit- convenience analysis in the counselling of patients and methods to monitor the treatment effect, including markers for subclinical inflammation. LÄS MER
2. Mantle cell lymphoma strategies in primary treatment
Sammanfattning : Mantle cell lymphoma (MCL) is associated with poor prognosis due to an aggressive clinical course. Being a rare disease, there are few randomized trials in MCL and there is no defined golden standard in primary treatment. LÄS MER
3. Burkitt lymphoma and diffuse large B-cell lymphoma – therapeutic strategies and pathogenetic mechanisms
Sammanfattning : Burkitt lymphoma (BL) is a rare, aggressive disorder constituting 1% of all non-Hodgkin lymphoma. Diffuse large B-cell lymphoma (DLBCL) is more common, accounting for 30% of malignant lymphoma. Standard treatment for adult BL and for certain subgroups of patients with DLBCL remains to be defined due to paucity of randomised trials performed. LÄS MER
4. Life and death of human B cells in health and disease
Sammanfattning : B cells provide one of the key mechanisms of immunological memory, which is theproduction of neutralising antibodies. How B cells respond to infections and vaccinationgives clues to how the development of the immunological memory is facilitated, and canthus lead to a deeper understanding of why the immune system sometimesmalfunctions. LÄS MER
5. Rituximab-induced neutropenia : clinical and patophysiological studies
Sammanfattning : Rituximab is a monoclonal antibody directed against the CD20 antigen on normal and neoplastic B-lymphocytes. It was originally developed for treatment of lymphomas as a targeted therapy against CD20 positive non-Hodgkin lymphomas (NHL). More recently, its use has expanded into patients with rheumatic diseases. LÄS MER